



# Case (TVC)

**Sanghoon Shin**  
**Division of Cardiology**  
**NHIS Ilsan Hospital**


# TVC NIRS IVUS




# pLAD- TVC




# TVC at pLAD




# TVC at pLAD




# TVC at pLAD



# pRCA




# TVC-pRCA








# pRCA




# pRCA



# TVC




- MLA 2.4mm<sup>2</sup>
- PB 78%
- LCBI max 641



- MLA 3.8mm<sup>2</sup>
- PB 83%
- LCBI max 91

**Which lesion should be treated?  
Which lesion could be deferred?**

# PROSPECT



Stone GW et al. *NEJM* 2011;364:226-35

# PROSPECT: Multivariable Correlates of Non-Culprit Lesion Related Events



## Independent predictors of lesion level events by Cox Proportional Hazards regression

Variable	HR (95% CI)	p-value
<b><math>PB_{MLA} \geq 70\%</math></b>	<b>5.03 [2.51, 10.11]</b>	<b>&lt;0.0001</b>
<b>VH-TCFA</b>	<b>3.35 [1.77, 6.36]</b>	<b>0.0002</b>
<b><math>MLA \leq 4.0 \text{ mm}^2</math></b>	<b>3.21 [1.61, 6.42]</b>	<b>0.001</b>
<b>Lesion length <math>\geq 11.6 \text{ mm}</math></b>	<b>1.97 [0.94, 4.16]</b>	<b>0.07</b>
<b><math>EEM_{MLA} &lt; 14.3 \text{ mm}^2</math></b>	<b>1.30 [0.62, 2.75]</b>	<b>0.49</b>


Variables entered: minimal lumen area (MLA), plaque burden at the MLA, external elastic membrane at the MLA, lesion length, distance from the coronary ostium to the MLA, remodeling index, thin-cap fibroatheroma, insulin-requiring diabetes and prior percutaneous coronary intervention

Stone GW et al. *NEJM* 2011;364:226-35

# TVC




- **MLA 2.4mm<sup>2</sup> ≤ 4.0 mm<sup>2</sup>**
- **PB 78% > 70%**
- **LCBI max 641**




- **MLA 3.8mm<sup>2</sup> ≤ 4.0 mm<sup>2</sup>**
- **PB 83% > 70%**
- **LCBI max 91**

# Thick CFA and Non-Culprit Lesion Related Events






# LCBI and Clinical outcomes



No. at Risk	0	90	180	270	360
LCBI < Median	101	99	99	97	91
LCBI ≥ Median	102	94	92	86	83

Oemrawsingh RM, et al. *J Am Coll Cardiol.* 2014


- 203 patients
- 1 yr FU
- HR=4.04



No at risk	0	200	400	600	800
maxLCBI <sub>max</sub> ≥ 400	21	16	12	5	0
maxLCBI <sub>max</sub> < 400	100	97	87	47	13

Madder RD, et al. *Eur Heart J Cardiovasc Imaging.* 2016


- 121 patients
- 2 yr FU
- HR=10.2



No. at risk	0	1	2	3	4
LCBI Q1 (<83.0)	68	66	52	43	29
LCBI Q2 (≥83.0-227.0)	68	61	47	40	31
LCBI Q3 (≥227.0-360.0)	67	55	42	35	22
LCBI Q4 (≥360.0)	70	53	41	31	26

Schuurman AS, et al. *Eur Heart J.* 2017

- 275 patients
- 4yr FU
- HR=3.22



Number at risk	0	500	1000	1500	2000	2500
LCBI ≥ 77	13	9	8	6	5	1
LCBI < 77	26	23	21	20	17	1

Danek BA, et al. *Cardiovasc Revascularization Med.* 2017

- 239 patients
- 5 yr FU
- HR=14.05


**High LCBI = poor clinical outcomes**

# LRP Study

- Can intravascular NIRS imaging identify Vulnerable Patients and Vulnerable Plaques during a 24-month period?
- **Vulnerable Patient** : Association between maxLCBI4mm in all imaged arteries and future patient-level non-culprit MACE
- **Vulnerable Plaque**: Association between maxLCBI4mm in a segment and incidence of future non-culprit MACE\* in same segment


# LRP study

## Study Flow Diagram




# NC-MACE

## Per Patient





## Per Plaque




**18% increase per 100 unit**  
**87% higher MACE in maxLCBI<sub>4mm</sub> > 400**

**45% increase per 100 unit**  
**4-fold higher MACE in maxLCBI<sub>4mm</sub> > 400**

# TVC



- **MLA 2.4mm<sup>2</sup> ≤ 4.0 mm<sup>2</sup>**
- **PB 78% > 70%**
- **LCBI max 641 > 400**



- **MLA 3.8mm<sup>2</sup> ≤ 4.0 mm<sup>2</sup>**
- **PB 83% > 70%**
- **LCBI max 91**

**Now, You saw the vulnerable plaque...**

**So, Will you treat it using PCI?...**